Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR-Cas9 screen

Mara Mennuni², Roberta Filograna¹, Andrea Felser¹², Nina A Bonekamp³⁴, Patrick Giavalisco⁵, Oleksandr Lytovchenko¹ & Nils-Göran Larsson¹#

Abstract

Cancer cells depend on mitochondria to sustain their increased metabolic need and mitochondria therefore constitute possible targets for cancer treatment. We recently developed small-molecule inhibitors of mitochondrial transcription (IMTs) that selectively impair mitochondrial gene expression. IMTs have potent antitumor properties in vitro and in vivo, without affecting normal tissues. Because therapy-induced resistance is a major constraint to successful cancer therapy, we investigated mechanisms conferring resistance to IMTs. We employed a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)- (CRISP-associated protein 9) whole-genome screen to determine pathways conferring resistance to acute IMT1 treatment. Loss of genes belonging to von Hippel–Lindau (VHL) and mammalian target of rapamycin complex 1 (mTORC1) pathways caused resistance to acute IMT1 treatment and the relevance of these pathways was confirmed by chemical modulation. We also generated cells resistant to chronic IMT treatment to understand responses to persistent mitochondrial gene expression impairment. We report that IMT1-acquired resistance occurs through a compensatory increase of mitochondrial DNA (mtDNA) expression and cellular metabolites. We found that mitochondrial transcription factor A (TFAM) downregulation and inhibition of mitochondrial translation impaired survival of resistant cells. The identified susceptibility and resistance mechanisms to IMTs may be relevant for different types of mitochondria-targeted therapies.

Keywords cancer; chemoresistance; CRISPR-Cas9 screen; inhibitor of mitochondrial transcription; mtDNA

Subject Categories Cancer; Metabolism

DOI 10.15252/embr.202153054 | Received 14 April 2021 | Revised 12 October 2021 | Accepted 19 October 2021 | Published online 15 November 2021

EMBO Reports (2022) 23: e53054

Introduction

Mitochondria contain their own DNA (mitochondrial DNA, mtDNA), which in mammals encodes 13 subunits of the oxidative phosphorylation (OXPHOS) system, as well as mitochondrial ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs) (Anderson et al, 1981; Bibb et al, 1981). Expression of mtDNA is required for proper OXPHOS function, and its disruption causes a variety of diseases, including metabolic disorders and neurodegeneration (Chinnery, 2015; Gustafsson et al, 2016; Kauppila et al, 2017). In the last decades, mitochondrial function has also been shown to be important for the development and progression of cancer (Funes et al, 2007; Viale et al, 2014; Hensley et al, 2016; Gammage & Frezza, 2019; Vasan et al, 2020). The accumulation of mtDNA mutations in cancer is a well-established phenomenon, but it is a matter of debate whether these mutations are mere passengers or tumor drivers. The contribution of mtDNA mutations seems to be dependent on the type and stage of the tumor. The mtDNA mutation pattern in some tumors is compatible with driver properties (Gopal et al, 2018; Gorelick et al, 2021), whereas other types of mutations, for example protein-truncating mutations, undergo negative selection in many cancers (Ju et al, 2014; Stewart et al, 2015; Yuan et al, 2020). In line with a proposed role for mtDNA in cancer, many groups have provided proof-of-concept that inhibition of OXPHOS or mitochondrial translation can indeed impair tumor growth (Skrtič et al, 2011; Boukalova et al, 2016; Reed et al, 2016; Molina et al, 2018; Lee et al, 2019; Shi et al, 2019).

As an alternative strategy to the direct inhibition of OXPHOS, we recently developed small-molecule inhibitors of mitochondrial transcription (IMTs) that strongly impair biogenesis of the OXPHOS system (Bonekamp et al, 2020). The IMTs, including IMT1 used in this study, are highly specific allosteric inhibitors of the mammalian mitochondrial RNA polymerase (POLRMT) and efficiently impair the transcription of mtDNA, which, in turn, abolishes OXPHOS system biogenesis (Bonekamp et al, 2020). IMTs reduce the growth of
human tumor cells in vitro and in mouse xenografts in vivo (Bonekamp et al., 2020). The importance of mtDNA transcription in tumor development is further underscored by a recent study where POLRMT levels were manipulated in human cancer cells (Zhou et al., 2021).

Treatment-induced drug resistance is a major problem in cancer and it can be explained by a reprogramming of metabolism and clonal selection of therapy-unresponsive cancer cells (Swanton, 2012). Furthermore, therapy-resistant cancer cells, sometimes also referred to as cancer stem cells, often rely heavily on OXPHOS for their persistence (Funes et al., 2007; Viale et al., 2014; Kuntz et al., 2017; Valle et al., 2018). To gain insights into potential mechanisms that can confer resistance to IMTs, we performed an unbiased whole-genome CRISPR-Cas9 screen (clustered regularly interspaced short palindromic repeats)-(CRISP-associated protein 9) of IMT1-treated cells (Shalem et al., 2014; Katigbak et al., 2016; Sharma & Petsalaki, 2018) and also generated an IMT1-resistant cell line through chronic IMT1 treatment. Our findings show that loss of genes in the von Hippel–Lindau (VHL) tumor suppressor and the mammalian target of rapamycin complex 1 (mTORC1) pathways confers resistance to acute IMT1 treatment, whereas further impairment of mitochondrial function, such as inhibition of mitochondrial translation and reduction of mtDNA copy number, increases sensitivity to IMT1 treatment.

## Results

### IMT1 treatment leads to progressive loss of mtDNA expression and cell death

The RKO colon cancer cells are established hosts for CRISPR-Cas9 genetic screens (Schmierer et al., 2017; Sayed et al., 2019) and we therefore characterized them further with respect to IMT1 sensitivity. We have previously demonstrated that around one third of a panel of 89 cancer cell lines are sensitive to IMT1 (Bonekamp et al., 2020), which reflects the heterogeneity of cancer cell lines. Besides the RKO cells, we included two additional IMT1-sensitive cell lines, cervix (HeLa) and pancreatic cancer cell lines (MiaPaCa-2), in this initial phase of the study. We investigated the viability of IMT1-treated RKO, HeLa, and MiaPaCa-2 cells and found that all had IC₅₀ values below 1 μM (RKO: 521.8 nM, MiaPaCa-2: 291.4 nM, and HeLa: 29.9 nM) (Fig 1A). There was a fast drop in mitochondrial transcript levels in IMT1-treated HeLa cells, with half-lives ranging between 37 and 321 min (Fig EV1A). Similarly, mitochondrial transcript levels were dramatically reduced after 96 h in IMT1-treated RKO cells (Fig 1B). The reduction of mitochondrial gene expression resulted in a substantial decrease in the OXPHOS protein steady-state levels, as determined by western blots of RKO cells (Fig 1C). The levels of subunits of complex I (NADH-ubiquinone oxidoreductase subunit B (NDUFB8)) and complex IV (cytochrome c oxidase subunit 2 (COX2)) dropped below the limit of detection in response to treatment with 1 μM IMT1 for 96 h, whereas subunits of complex III (ubiquinol-cytochrome c reductase core protein 2 (UQRC2)) and complex V (ATP Synthase F1 subunit alpha (ATPS5A)) were much less affected (Fig 1C). Whole-cell quantitative proteomic analyses showed a significant reduction of mitochondrial proteins, especially of those required for mitochondrial translation and OXPHOS, whereas proteins localized to other cellular compartments remained mostly unaffected in IMT1-treated RKO cells (Figs 1D and EV1B and Dataset EV1). These data demonstrate that IMT1 inhibits mitochondrial gene expression in RKO cells to a similar extent as previously reported for HeLa and A2780 cells (Bonekamp et al., 2020).

### CRISPR-Cas9 screening reveals that VHL and mTORC1 loss promotes resistance to IMT1

To identify factors that can modulate sensitivity to IMT1, we performed a genome-wide CRISPR-Cas9 screen in RKO cells. Cas9-expressing RKO cells were transduced with a whole-genome lentiviral single guide RNA (sgRNA) library and allowed to grow with or without 1 μM IMT1 for 10 days for clonal selection (Fig 1E). The barcoded guides were sequenced to identify genes that were enriched or depleted at the end of the experiment. Gene knockouts, which conferred resistance or increased susceptibility to IMT1 treatment, were referred to as positive and negative hits, respectively (Fig 1E). The CRISPR-Cas9 screen revealed that VHL gene was the most significant and enriched positive hit (Fig 1F and Dataset EV2). Moreover, most other genes that increased cell survival after IMT1 treatment belonged to mTORC1 pathway (Fig 1F and Dataset EV2).

To validate the positive hits identified by the CRISPR-Cas9 screening, we tested whether chemical perturbation of the VHL and mTORC1 pathways could increase IMT1 tolerance in RKO, MiaPaCa-2, and HeLa cells. Treatment of RKO cells with the mTORC1 inhibitors rapamycin or temsirolimus (Sehgal et al., 1975; Heitman et al., 1991; Rini, 2008) reduced the phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), which is a downstream target of mTORC1 (Fig 2A). Both rapamycin and temsirolimus were able to rescue cell death in IMT1-treated RKO cells (Figs 2B and EV2A). Rapamycin also increased survival of IMT1-treated MiaPaCa-2 (Fig 2C) and HeLa cells (Fig 2D).

Because of the well-established role of VHL as tumor suppressor in modulating the hypoxia-inducible factor 1α (HIF1α) (Wang & Semenza, 1993; Maxwell et al., 1999), we decided to use FG4592, a prolyl hydroxylase (PHD) inhibitor that stabilizes HIF1α at normal oxygen levels (Guenzler-Pukall et al., 2003; Rabinowitz, 2013). Treatment of cells with FG4592 thus mimics the reduced degradation of HIF1α that occurs during hypoxia (Jain et al., 2016; Joharapurkar et al., 2018) or in the absence of the VHL protein. Treatment of RKO cells with FG4592 showed that HIF1α was stabilized under standard tissue culture conditions (Fig 2E). Notably, FG4592 treatment significantly increased the viability of RKO (Fig 2F), MiaPaCa-2 (Fig 2G), and HeLa (Fig 2H) cells, when administered in the presence of IMT1.

To understand whether these resistance mechanisms are conserved, we included additional IMT1-sensitive cancer cell lines that had been identified in our previous study (Bonekamp et al., 2020). We found that rapamycin improved tolerance to IMT1 treatment in five of the seven tested cell lines (Figs 2I and EV2B–E), whereas FG4592 partially restored viability in the presence of IMT1 of four out of seven cell lines (Figs 2J and EV2F–I). Rapamycin and FG4592 conferred resistance to IMT1 in cancer cell lines of different tissue origins, showing that these resistance mechanisms are not specific to a certain tumor type.
Figure 1. Whole-genome CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)-(CRISP associated protein 9) genetic screen reveals mechanisms of resistance to IMT1.

A  Dose–response viability curves in the presence of increasing concentrations of IMT1 for 1 week. Viable cells were counted and normalized to dimethyl sulfoxide (DMSO)-treated controls. Data are expressed as mean ± SD of n = 3 independent experiments with four technical replicates. The IC_{50} values were calculated with non-linear least squares fit; RKO: 52.1 ± 8 nM, MiaPaCa-2: 291.4 ± 8 nM, and HeLa: 29.9 ± 8 nM.

B  Mitochondrial transcript levels measured by quantitative real-time polymerase chain reaction (qRT–PCR) in RKO cells after 96 h of 1 μM IMT1 treatment. Data are relative to dimethyl sulfoxide (DMSO)-treated controls and are expressed as mean ± SD of n = 4 independent experiments. Ordinary one-way ANOVA was used for comparisons to DMSO-treated controls (RNR1, RNR2, MT-COX2, MT-ATP6, and MT-ND1: ***P < 0.0001).

C  Representative western blot images of oxidative phosphorylation (OXPHOS) protein levels of RKO cells at increasing concentrations of IMT1. Actin B (ACTINB) is shown as loading control.

D  Volcano plot showing proteomic changes of RKO cells treated with 1 μM IMT1 for 96 h. Data are plotted as average log_{2} fold change (LFC) versus log_{10} of adjusted P-value of dimethyl sulfoxide (DMSO)-treated controls; mitochondrial proteins are highlighted in red.

E  Schematic description of the experimental CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)-(CRISP-associated protein 9) approach: Cas-9 expressing-RKO cells were transduced with a genome-wide pooled knockout CRISPR library and passaged in the presence of either IMT1 or DMSO (dimethyl sulfoxide) for guide selection. After cell collection and DNA isolation, the guides were sequenced and quantified in each population. Created with www.BioRender.com.

F  CRISPR (clustered regularly interspaced short palindromic repeat) guides enriched (positive hits) in IMT1-treated RKO cells plotted as log_{2} fold change (LFC) versus log_{10} of adjusted P-value. Mammalian target of rapamycin complex 1 (mTORC1) and von Hippel–Lindau (VHL) pathway-related genes are reported in green and blue, respectively.
Rapamycin and FG4592 confer resistance to IMT1 toxicity

We next assessed the effect of rapamycin and FG4592 on mitochondrial function. We first tested whether the two compounds had an impact on mitochondrial biogenesis, but found no significant increase in the levels of mtDNA (Fig EV3A) or mitochondrial transcripts (Fig EV3B) in RKO cells treated with IMT1 in combination with rapamycin or FG4592. In line with this, there was no induction of the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) expression in either of these conditions (Fig EV3C). Similarly, rapamycin treatment had no effect on mtDNA
Next, we assessed the production rate and the stability of mtDNA-encoded OXPHOS proteins by performing $^{35}$S-labeling of newly synthesized mitochondrial proteins in whole cells. We found a mild, but significant, increase in both the production rate (pulse) and the stability (chase) of newly synthesized mitochondrial proteins after IMT1 treatment in the presence of rapamycin (Fig 3A and B). In contrast, treatment of RKO cells with IMT1 in the presence of FG4592 did not result in significant changes in protein production rates or stability (Fig 3A and B). Consistent with this, the steady-state levels of the mitochondrial-encoded COX2 protein (Fig 3C and D) and oxygen consumption rates (OCRs) were higher if the IMT1 treatment was combined with rapamycin (Fig 3E and F), whereas the combination with FG4592 had no such effect (Fig 3C, D, E and G). The bioenergetic profile graph, which reports the contribution of OCR and extracellular acidification rate (ECAR) to cellular bioenergetics, showed a shift toward glycolysis in the presence of IMT1 (Fig 3E). However, the shift toward glycolysis was smaller, if IMT1 was combined with rapamycin, in comparison with IMT1 alone (Fig 3E). Based on these data, we conclude that rapamycin and FG4592 confer resistance to IMT1 treatment through distinct mechanisms.

Given the relationship between cellular energy homeostasis, nutrient availability, and autophagy (Yang et al., 2019), we determined whether changes in autophagy could account for the increased tolerance to IMT1 in the presence of rapamycin and FG4592. We estimated the cellular autophagic flux by assessing the accumulation of the microtubule-associated proteins 1A/1B light chain 3B (LC3BII) after the inhibition of lysosomal acidification with ammonium chloride and observed a marked decrease in LC3BII levels in the presence of IMT1 (Fig EV3H and I). We found that neither rapamycin nor FG4592 could normalize the reduced autophagic flux caused by IMT1 treatment. We therefore conclude that the protective action of rapamycin and FG4592 is likely not caused by the normalization of autophagy in IMT1-treated cells (Fig EV3H and I).

Dose-escalated chronic IMT1 treatment confers drug resistance to RKO cells

The CRISPR-Cas9 screen identified cellular responses promoting survival under acute inhibition of mitochondrial transcription. In order to understand the long-term cellular adaptations to the inhibition of mitochondrial transcription, which often occurs in disease states, we exploited an escalated-dose treatment approach (McDermott et al., 2014). We exposed RKO cells to sublethal IMT1 doses and gradually increased the drug concentration over several weeks to generate resistant lines. The IMT1 effect on viability and OXPHOS protein abundance was assessed at different time points during the generation of the resistant lines. When compared to the original RKO cell line, the cells chronically exposed to IMT1 for 2 months showed increased tolerance to IMT1. Exposure to 1 µM IMT1 for 7 days was lethal for RKO cells, but was not toxic for the resistant line (Fig 4A). In comparison with the original RKO cells, the resistant cells maintained OXPHOS protein levels (COX2 and NDUF8) at high IMT1 doses better (Fig 4B). While IMT1 completely abolished mitochondrial translation in RKO cells (Fig 4C and D, pulse), the resistant cells maintained mitochondrial translation rates at higher levels in the presence of IMT1, as shown in the $^{35}$S-labeling experiment (Fig 4C and D, pulse). No differences in protein stability were observed between the dimethyl sulfoxide (DMSO)-treated resistant and parental RKO cells in the 24-h chase experiment (Fig 4C and D, chase). The mtDNA transcript levels in IMT1-treated RKO cells were drastically reduced, whereas IMT1-treated resistant cells had near-normal levels of transcripts in comparison with untreated RKO cells (Fig 4E and F). Interestingly, the mtDNA levels were also higher in the IMT1-treated resistant line compared with IMT1-treated parental RKO cells, and reached levels corresponding to ~50% of the mtDNA levels of the controls (Fig 4G). The characterization of cellular bioenergetics performed with the Seahorse flux analyzer revealed that DMSO-treated resistant cells had lower basal OCR than DMSO-treated parental RKO cells (Fig 4H). While IMT1 treatment resulted in a strong reduction of respiration rates in RKO cells, the drop in OCR was smaller in IMT1-treated resistant cells (Fig 4H). These data show that the resistant cells can maintain higher mtDNA levels than the original RKO cells when treated with IMT1, which allow them to maintain near-normal levels of mtDNA-encoded transcripts and mitochondrial proteins, resulting in a partial rescue of OCR.

Increased glycolysis, reduced drug uptake, or mutations in the drug target do not explain IMT1-induced resistance

Reliance on glycolysis is one of the mechanisms by which cancer cells can compensate for impaired OXPHOS. To understand whether increased glycolysis plays a role in IMT1-induced resistance, we measured ECAR, but found no significant differences between the RKO and IMT1-resistant RKO cells (Fig 5A). IMT1 treatment caused a twofold increase in ECAR in the RKO cells, whereas no difference was found in the IMT1-resistant RKO cells (Fig 5A). The bioenergetic profile graph revealed a mild switch toward glycolysis in the IMT1-treated resistant cells (Fig 5B). In agreement with these data, we found no difference in the sensitivity to treatment with 2-deoxy-D-glucose (2DG), a well-known glycolysis inhibitor (Woodward & Hudson, 1954), between RKO and IMT1-resistant RKO cells (Fig 5C). Therefore, these findings exclude increased reliance on glycolysis as an important mechanism for IMT1-acquired resistance.

Drug resistance is often caused by multiple drug resistance (MDR) mechanisms (Szakács et al., 2006). Common MDR mechanisms include reduced uptake and increased efflux of drugs from the cell through the plasma membrane by ABC transporters (Szakács et al., 2006; Swanton, 2012). To investigate this possibility further, we measured the levels of IMT1 in RKO and IMT1-resistant RKO cells, and found no differences in the extracellular concentration (Fig 5D), whereas the intracellular concentration was higher in the resistant line (Fig 5E), likely because these cells were continuously maintained by culture in IMT1-containing medium. These findings exclude decreased cellular absorption or increased excretion of IMT1 as a resistance mechanism.

We have previously performed cryo-electron microscopy (cryo-EM) studies and identified a specific pocket of POLRMT where the IMT1 binds (Bonekamp et al., 2020). An unbiased mutagenesis screen has shown that substitutions of four amino acids (L796, F813, L816, and A821) clustered in this pocket confer resistance to IMTs (Bonekamp et al., 2020). We therefore sequenced this POLRMT region in the IMT1-resistant RKO cells, but found no mutations (Fig 5F). These findings support the conclusion that the dose-escalation
**Figure 3.** Rapamycin, but not FG4592, treatment sustains oxidative phosphorylation (OXPHOS) function in the presence of IMT1.

- **A** ³⁵S-labelling of newly synthesized mitochondrial-encoded proteins of RKO cells treated either with dimethyl sulfoxide (DMSO), IMT1, rapamycin, and FG4592 alone or in combination with IMT1. Left: pulse labeling; right: 24-h chase in normal medium. Putative mitochondrial proteins are reported on the right-hand side of the gel, molecular weights on the left. Coomassie staining shows equal protein loading; the image is representative of n = 4 independent experiments.
- **B** Densitometric quantification of the ND5, COX1, ND4 band from n = 4 ³⁵S-labelling experiments. Data are expressed as mean values ± SD. Statistical significance was calculated with one-way ANOVA test. Paired comparisons: IMT1 versus IMT1 + RAPA pulse: *P = 0.035; IMT1 versus IMT1 + RAPA chase: *P = 0.046; IMT1 versus IMT1 + FG4592 pulse and chase: non-significant.
- **C** Western blot analyses of oxidative phosphorylation (OXPHOS) protein steady-state levels of RKO cells after treatment with dimethyl sulfoxide (DMSO), IMT1, rapamycin, rapamycin with IMT1, FG4592, and FG4592 with IMT1. Actin B (ACTINB) is shown as loading control.
- **D** Densitometric quantification of cytochrome c oxidase subunit 2 (COX2) protein levels from n = 4 experiments. Data are expressed as mean values ± SD. Statistical significance was calculated with one-way ANOVA test. Paired comparisons: IMT1 versus IMT1 + RAPA pulse: *P = 0.034; IMT1 versus IMT1 + FG4592: *P = 0.046; IMT1 + RAPA versus IMT1 + FG4592: non-significant.
- **E** Bioenergetic profiles measured with Seahorse flux analyzer showing the contribution of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to cellular bioenergetics upon the aforementioned treatments. Data represent the mean ± SEM of n = 3 independent experiments.
- **F, G** Cellular oxygen consumption rate (OCR) measured with Seahorse extracellular flux analyzer after sequential addition of different modulators of mitochondrial function. RKO cells were treated with dimethyl sulfoxide (DMSO), rapamycin (F), or FG4592 (G) in the presence or absence of IMT1. Data are expressed as the mean ± SEM of n = 3 independent experiments with six technical replicates. Statistical significance was calculated with one-way ANOVA test. DMSO-treated controls versus: IMT1: P = 0.0008; RAPA: P = 0.1578; RAPA + IMT1: P = 0.0034; FG4592: P = 0.872; FG4592 + IMT1: P = 0.0029. Paired t-test of IMT1 versus RAPA + IMT1: P = 0.034; IMT1 versus FG4592 + IMT1: non-significant.
The resistant cell line maintains higher metabolite levels in the presence of IMT1

Having excluded mutations of the POLRMT target enzyme and MDR mechanisms as explanations for IMT1 resistance, we focused on identifying metabolic adaptations to IMT1 chronic treatment. First, we performed whole-cell proteomic analyses in RKO cells and IMT1-resistant RKO cells treated with 1 µM IMT1 for 96 h and found quite similar proteomic changes (Pearson’s r = 0.59; Fig 6A and B and Dataset EV1), despite the previously observed differences in cell survival (Fig 4A). The proteins with changed expression (Fig 6B and Dataset EV1) and the involved metabolic pathways (Fig 6A) were similar in RKO cells and IMT1-resistant RKO cells, although the changes were less pronounced in the resistant cells. As reported in our previous paper, IMT1 induces a cellular energy crisis leading to depletion of metabolites and eventually cell death (Bonekamp et al, 2020). We therefore performed metabolic analyses and found a strong reduction in cellular nucleotide levels, tricarboxylic acid (TCA) cycle intermediates and, to a lesser extent, amino acids in RKO cells treated with IMT1 in comparison with DMSO-treated controls (Fig 6C and Dataset EV3). However, metabolites were maintained at higher levels after IMT1 treatment of IMT1-resistant RKO cells in comparison with IMT1 treatment of RKO cells (Fig 6C and Dataset EV3), thus preventing a critical decline of cellular metabolism.

Because mTORC1 inhibition and HIF1α stabilization confer resistance to IMT1-sensitive cells (Figs 2B–D and EV2A–C), we investigated whether these pathways were affected in the IMT1-resistant RKO line. HIF1α was not detected in the proteomic analysis of resistant cells (Dataset EV1), suggesting that HIF1α stabilization does not explain resistance. No significant changes in mTORC1-related proteins were identified in the same dataset (Dataset EV1). However, changes in mTORC1 activity may occur without the protein levels being affected and we therefore assessed the extent of 4EBP1 phosphorylation as a readout of mTORC1 activity. Interestingly, IMT1-resistant RKO cells showed reduced phosphorylation of the mTORC1 target 4EBP1 in comparison with RKO cells (Fig 6D). Rapamycin and temsirolimus promoted survival of cells acutely exposed to IMT1 (Figs 2B–D and EV2A–C) and our results argue that mTORC1 inhibition may also be of importance in chronic IMT1 resistance.

Inhibition of mitochondrial translation and TFAM downregulation can overcome IMT1 resistance

The CRISPR-Cas9 screen, in addition to positive hits (Fig 1F), also identified a number of genes whose inactivation increased the cellular sensitivity to IMT1 (negative hits), for example, genes encoding OXPHOS subunits, the mitochondrial transcription factor A (TFAM), and several mitochondrial translation factors (Fig 7A and Dataset EV2). To test the role of mitochondrial translation further, we treated cells with chloramphenicol (CAP), a well-known inhibitor of mitochondrial translation (McKee et al, 2006). We performed a dose–response titration in monolayer cultures of RKO cells and found that CAP concentrations below 1 µg/ml did not cause cell death (Fig EV4A), despite decreasing the levels of the mtDNA-encoded COX2 protein (Fig EV4B). Next, we proceeded to treat RKO cells and IMT1-resistant RKO cells with this sublethal dose of CAP (1 µg/ml) and found no effect on cell viability (Figs EV4C and 7B). Although the IMT1-resistant cells showed no response to IMT1 and CAP when administered individually, the combined treatment with both drugs caused a 50% drop in cell viability in monolayers of cells (Fig 7B), showing an additive effect of the two drugs. Importantly, IMT1 and CAP co-treatment did not affect the viability of primary fibroblasts from healthy donors (Fig EV4D). We then proceeded to analyze spheroids, as this culture system resembles better some aspects of tumor biology than monolayer cultures (Minchinton &}

© 2021 The Authors

EMBO reports 23: e53054 | 2022 7 of 18
**Figure 4.**

**A**

![Graph showing viability of cells](image)

**B**

| DMSO | 0.1 nM | 1 nM | 10 nM | 100 nM |
|------|-------|------|-------|--------|
| RKO  |       |      |       |        |
| IMT1 |       |      |       |        |

**C**

| Pulse | Chase 24h |
|-------|-----------|
| DMSO | IMT1 |
| RKO  | Res |
| Res  | Res |

**D**

| DMSO | IMT1 |
|------|------|
| RKO  | Res  |
| Res  | IMT1 |

**E**

| Relative transcript levels |
|---------------------------|
| MT-ND1 | MT-RNR1 | MT-ATP6 |
| DMSO | IMT1 |
| RKO | Res |

**F**

| Relative mtDNA copy number |
|-----------------------------|
| MT-ND1 | MT-ATP6 | MT-CYTB |
| DMSO | IMT1 |
| RKO | Res |

**G**

| Relative mtDNA copy number |
|-----------------------------|
| MT-ND1 | MT-ATP6 | MT-CYTB |
| DMSO | IMT1 |
| RKO | Res |

**H**

| OCR (pmoles/min/cells) |
|------------------------|
| Oligo | FCCP | Rot,AA | 2DG |
| RKO DMSO | IMT1 |
| Resistant DMSO | Resistant IMT1 |
Tannock, 2006). We treated spheroids of RKO cells with CAP and found that doses above 1 µg/ml impaired their growth (Fig EV4E). When we treated RKO cells with a combination of IMT1 and CAP in increasing concentrations, we found an additive effect on spheroidal growth (Fig EV4F). Next, we treated spheroids of IMT1-resistant RKO cells with IMT1 and CAP and found a similar effect (Fig 7C).

To understand whether the CAP could sensitize other IMT1-resistant cell lines to IMT1 treatment, we tested this treatment on four additional cell lines. We found that 1 µg/ml of CAP mildly reduced viability in the presence of IMT1 in three of the four IMT1-resistant cell lines tested (Fig 7D). When the concentration of CAP was raised to 100 µg/ml, the drop in cell number was much stronger (Fig EV4G). We also tested whether the inhibition of glycolysis can sensitize IMT-resistant cell lines to IMT1 treatment, but found only a mild difference in viability when a combination of 1 mM 2DG and IMT1 was administered (Fig EV4H).

Since the IMT1-resistant cells maintained higher levels of mtDNA in the presence of IMT1 (Fig 4G), we investigated whether decreased mtDNA levels could affect survival. To this end, we knocked down the expression of TFAM, which directly controls

---

Figure 5. Increased glycolysis, reduced drug uptake, or mutations in the drug target do not explain IMT1-induced resistance.

A Extracellular acidification rate (ECAR) measured by Seahorse extracellular flux analysis in dimethyl sulfoxide (DMSO) and IMT1-treated RKO and IMT1-resistant cells. Data are expressed as the mean ± SEM of n = 3 independent experiments with six technical replicates. Statistical significance was calculated with one-way ANOVA test for multiple comparisons. RKO DMSO versus RKO + IMT1: **P = 0.0019; RKO + IMT1 versus resistant + IMT: *P = 0.0214; RKO DMSO versus resistant DMSO: non-significant.

B Bioenergetic profiles measured with Seahorse flux analyzer, showing the contribution of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to cellular bioenergetics in RKO and IMT1-resistant RKO cells treated with and without IMT1. Mean of n = 3 independent experiments ± SEM.

C Dose–response viability curves during treatment with serial dilution of IMT1 for 1 week in RKO and IMT1-resistant RKO cells. Data are expressed as the mean ± SD of n = 3 experiments.

D, E IMT1 extracellular (D) and extracellular (E) concentrations measured in the medium at 0, 2, and 24 h of IMT1 treatment in RKO and IMT1-resistant RKO cells. Mean values ± SEM of n = 3 experiments.

F Schematic representation of the IMT1-binding region on the human mitochondrial RNA polymerase (POLRMT) sequence, adapted from (Hillen et al, 2018). Previously identified mutations conferring resistance to IMT1 are reported in red (Bonekamp et al, 2020). Representative results of n = 3 independent sequencing experiments of the POLRMT gene in RKO and IMT1-resistant RKO cells at the region of interest.
mtDNA levels (Filograna et al., 2021; Bonekamp et al., 2021). We used two different small interfering RNAs (siRNAs) in IMT1-resistant cells and both siRNAs caused a gradual decrease in TFAM protein levels (Fig EV4) and mtDNA levels (Filograna et al., 2021). We also found that TFAM siRNA#2 caused a stronger decrease of TFAM protein levels and mtDNA copy number than TFAM siRNA#1 (Fig 7E and F). Consistently, there was a significant decrease in cell viability when IMT1-resistant cells were transfected with TFAM siRNA#2 in comparison with cells transfected with control siRNAs, in the presence of IMT1 (Fig 7G). The importance of TFAM in preventing IMT1 toxicity is also supported by the CRISPR-Cas9 screen where TFAM was identified as a negative hit (Fig 7A).

**Discussion**

In this study, we used IMT1, a highly specific allosteric inhibitor of POLRMT (Bonekamp et al., 2020), to study resistance mechanisms...
in treated cancer cells. We used an unbiased whole-genome CRISPR-Cas9 screen to identify resistance mechanisms induced by acute IMT1 treatment and found that the loss of mTORC1 and VHL expression was protective. The mTORC1 protein complex functions as a nutrient sensor and controls cytosolic translation, which makes it one of the master regulators of cell proliferation and cell fate decisions. Inhibitors of mTORC1 have been proposed for cancer treatment (Podsypanina et al., 2001; Thimmaiah et al., 2010), but the outcomes from clinical studies have not been conclusive (Sun, 2013). It has also been proposed that mTORC1 activation may occur although nutrients are scarce in cancer cells and that rapamycin treatment can be protective and prevent cell death (Fumarola et al., 2005; Choo et al., 2010; Hung et al., 2012; Villar et al., 2017). The data we present here support this model because the decreased cell viability caused by IMT1 treatment was rescued by rapamycin. Consistent with these results, rapamycin treatment has also been reported to slow disease progression and prolong survival in mice with mitochondrial dysfunction (Zheng et al., 2016; Khan et al., 2017).

When oxygen levels are low, the stabilization of HIF1α induces a transcriptional reprogramming of the cellular metabolism to decrease the dependency on mitochondrial function (Papandreou et al., 2006; Zhang et al., 2007). Loss of VHL, which causes oxygen-independent stabilization of HIF1α, is reported to increase the predisposition to some cancers (Giles et al., 2006; Kaelin, 2008). The PHD inhibitor FG4592 (Roxadustat) is routinely used in vitro as an experimental tool to stabilize HIF1α (Jain et al., 2016) and was under FDA evaluation for anemia treatment (https://clinicaltrials.gov/ct2/show/NCT01750190; Guenzler-Pukall et al., 2003; Rabowitz, 2013; Joharapurkar et al., 2018). Our results show that FG4592 stabilizes HIF1α and protects against cell death induced by IMT1, which is in good agreement with published data showing that loss of VHL or FG4592 treatment rescues the effects of toxins that inhibit OXPHOS (Jain et al., 2016). It has been reported that hypoxia can prevent neurodegeneration in a mouse model with mitochondrial dysfunction (Jain et al., 2016; Ferrari et al., 2017). However, stabilization of HIF1α by genetic interventions was not sufficient to prevent neurodegeneration in this model (Jain et al., 2019), where complex I becomes unstable due to the absence of the NADH dehydrogenase (ubiquinone) iron-sulfur protein 4 (NDUFS4) subunit (Sterky et al., 2012). The pathology was instead attributed to a direct effect of high oxygen tension in the brain (Jain et al., 2019). In contrast, HIF1α has a direct role in ameliorating the acute effects of impaired mtDNA expression in IMT1-treated tumor cells. It is possible that HIF1α expression is of importance in the large subgroup of mitochondrial diseases where the biogenesis of the whole OXPHOS system is impaired, whereas it may have no role in mitochondrial diseases caused by impaired stability of a single complex.

Alterations of cellular metabolism and mitochondrial function are well-known hallmarks of cancer (Hanahan & Weinberg, 2011). In contrast to many specialized postmitotic cells, cancer cells do not only need mitochondria to sustain ATP production, but also to supply a variety of metabolic intermediates and reducing equivalents needed for synthesis of biomass during cellular proliferation (Vander Heiden et al., 2009; Vasan et al., 2020). Mitochondria are thus an emerging target for cancer treatment, but the resistance mechanisms induced by chronic inhibition of mitochondrial function are poorly understood. To investigate the effects of chronic IMT1 resistance, we used a dose-escalation approach in RKO cells. The IMT1-resistant RKO cells maintained mtDNA expression at higher levels than RKO cells, and this was sufficient to increase the levels of cellular metabolites. However, interventions to decrease mtDNA copy number (TFAM knockdown) or to impair mitochondrial translation (CAP treatment) decreased the survival of the IMT1-treated resistant cells. These findings argue that interventions at different levels in the mtDNA expression axis, for example, decrease of mtDNA copy number, mitochondrial transcription, or mitochondrial translation, act synergistically. A threshold effect seems to be important for cancer cell survival in both the acute and chronic IMT1-induced resistance. In fact, both rapamycin and chronic IMT1 treatments seem to confer resistance by maintaining...
Figure 7.
mtDNA-encoded gene products at higher levels. Also, inhibitors of mitochondrial translation, such as the FDA-approved drug tigecycline (Jia et al., 2016; Kuntz et al., 2017), have been effective in pre-clinical tumor models. Although the exact role of mtDNA level variation in cancer is not fully understood, an upregulation of mtDNA copy number commonly occurs in many tumors (Reznik et al., 2016; Filograna et al., 2021; Yuan et al., 2020). It is important to note that studies of humans (Larsson & Clayton, 1995; Stewart & Chinnery, 2015) and mice (Kauppila et al., 2016; Jiang et al., 2017; Filograna et al., 2019) with mitochondrial dysfunction have shown that mtDNA expression below a critical threshold level will lead to a cellular energy crisis. This threshold phenomenon likely explains why a modest increase of cellular respiration can drastically increase the levels of cellular metabolites and survival of cancer cells, as observed here.

Due to the extreme genetic heterogeneity of cancer cell lines, it is not surprising that responses to the inhibition of mitochondrial gene expression are not universal. However, we have identified a number of mechanisms that appear to be common to many cancer cell lines. The responses identified in this study should therefore be taken into consideration when future mitochondria-targeted therapies are developed.

Materials and Methods

Cell lines, cell culture conditions, and treatments

RKO (ATCC, CRL-2577), MiaPaCa-2 (ATCC, CRL-1420), HeLa (ATCC, CCL2), Calu-6 (ATCC, HTB-56), NCIH-460 (ATCC, HTB-177), DLD-1 (ATCC, CCL-221), HT-29 (ATCC, HTB-38), Capan-2 (ATCC, HTB-80), PANC-1 (ATCC, CRL-1469), A549 (DSMZ, ACC107), and HCT-15 (DSMZ, ACC-357) cells and primary fibroblasts were all maintained in Dulbecco’s modified Eagle’s medium (DMEM) GlutaMAX™ (Gibco, 31966-021) supplemented with 10% FCS, 1% penicillin and streptomycin, 1% glutamine, and 200 µg/ml of amphotericin B (Life Technologies, 15240-018). For the pools, cells were obtained and analyzed with the software Fiji (ImageJ) to determine the diameter of the spheroids.

Generation of IMT1-resistant RKO cells

Pool populations of RKO cells were subjected to dose-escalated treatments with IMT1. The cells were treated with increasing concentrations of the compound over several months, starting with a sublethal concentration of 10 nM for the first month, increased to 100 nM during the second, raised to and maintained at 1 µM during the following 4 months. The cells showed to adapt and survive to all IMT1 doses and to maintain the resistance phenotype over freeze-thaw cycles. Two independent batches of resistant cells were generated with the described approach and both showed to behave in the same way in respect to the parameters analyzed in this study.

Northern blotting and quantitative real-time PCR

The total RNA was extracted from cell pellets using TRIzol reagent (Life Technologies, 15596018) and spectrophotometrically quantified by measuring the absorbance at 260 nm. For quantification of the transcripts, the RNA was retrotranscribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814) and the relative complementary DNAs (cDNAs) were measured by the quantitative real-time polymerase chain reaction (qRT-PCR) using TaqMan Universal Master Mix II and probes (Applied Biosystems, 442873) and normalized to Actin B (ACTINB) cDNA. The assays were performed in technical triplicates on 384-well reaction plates (Applied Biosystems) in final volumes of 10 µl and according to the manufacturer’s guidelines. Transcript half-lives were determined at time curves of 0, 0.5, 1, 2, 4, 6, 24, 48, 72, and 96 h. Half-lives of mitochondrial transcripts were estimated by non-linear regression curve fitting using GraphPad Prism 5.0 software.
For northern blotting, 4 µg of extracted RNA was run on an agarose (1.2%) formaldehyde (18%) gel in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (Ambion), then transferred to Hybond-N+ nylon membranes (GE Healthcare) and hybridized with α-32P-CTP-labeled probes (PerkinElmer) for mitochondrial-encoded RNA species. The probes were generated using the 9-mer random primer kit, according to the manufacturer’s specifications (Agilent).

**DNA extraction, mtDNA copy number, and POLRMT sequencing**

Total DNA was extracted from cell pellets using QiAmp DNA extraction kit (Qiagen) according to the manufacturer’s specifications. Total DNA levels were measured and, after a ribonuclease (RNase) digestion step, the mtDNA copy number was measured via qRT-PCR using TaqMan probes against ND1, ATP6, and COX2 and normalized using 18S nuclear DNA. The assays were performed in technical triplicates on 384-well reaction plates (Applied Biosystems) in triplicate the OXPHOS cocktail, Abcam (ab110411); glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Abcam (ab8245); 4EBP1 total, Cell Signaling (9644); phospho-4Ebp1 (S65), Cell Signaling (9451); HIF1-α, Cell Signaling (14179); VHL, Cell Signaling (68547), TFAM, Abcam (ab131607), and LC3B Cell Signaling (#2775)). After washes in TBS-Tween, the membranes were incubated with anti-mouse or anti-rabbit secondary antibodies (GE Healthcare, NA9310V and NA9340V) for 1 h at room temperature. Proteins were detected using Clarity Western ECL Substrate (Bio-Rad, 170-5061). Densitometric quantification of western blot bands was performed using the software Fiji normalized for the loading control.

**Mitochondrial translation assay**

35S-labeling was performed, as previously described (Chomyn, 1996). Briefly, after washing with cytochalasin and methionine-free DMEM (Gibco, 21013024), the cells were incubated in the same medium supplemented with 1 mM glutamax, 1 mM sodium pyruvate (Life Technologies), and 10% dialyzed bovine serum. As much as 100 µg/ml of anisomycin (Sigma, A9789) was added for 20 min to inhibit the cytosolic protein synthesis and 3.7 MBq of 35S-L-methionine and cysteine mix (PerkinElmer, NEG77200) was added for 45 min to label the newly synthesized mitochondrial proteins. After harvesting, the cells were lysed on ice in phosphate-buffered saline solution (PBS) containing protease inhibitor cocktail (Roche, 4693116001), benzonase nuclease (Sigma, E1014 (2.25 U/ml)), and 0.1% n-dodecyl-β-D-maltoside (DDM) (Sigma, D4641). One percent SDS was then added to complete the lysis. For the chase experiment, cells were pre-treated with 50 µg/ml of chloramphenicol for 16 h before the experiment and collected 24 h after the 35S-labeling. Proteins (20–30 µg) per lane were loaded on pre-cast SDS–PAGE gels (Life Technologies). The gels were stained with Coomassie staining solution (50% methanol, 10% acetic acid, and 0.1% Coomassie Brilliant Blue R250 (Thermo Fisher, 20278)) to ensure equal loading. The gels were dried and exposed to phosphor screens and the signal was detected using Typhoon™ Phosphoimager. Densitometric quantification of band intensity was performed using the software Fiji and normalized for Coomassie-stained images of the gels.

**Western blotting**

After harvesting, the cell pellets were resuspended in PBS and lysed on ice with lysis buffer (4 mM Tris-HCl, 1 M NaCl, 4 mM ethylene-diaminetetraacetic acid (EDTA, Sigma), 2% Triton X-100 (Santa Cruz Biotechnology), 20% glycerol, 1× protease inhibitor cocktail, phosphatase inhibitor cocktail (Sigma, 4906845001), and 2.25 U/µl benzonase). After incubating on ice for 20 min, the samples were centrifuged for 20 min at 13,000 g, and the protein-containing supernatant was used for loading. Equal amounts of proteins were separated on NuPAGE gels (Life Technologies) depending on the separation profile needed. Proteins were transferred to 0.45-µm polyvinylidene fluoride membranes (PVDF, Millipore IPVH0010) and blocked in 5% milk Tris-buffered saline (TBS) solution containing 0.1% Tween for 1 h. The membranes were incubated with primary antibodies overnight at 4°C (Actin B, Abcam (ab8226); human total OXPHOS cocktail, Abcam (ab110411); glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Abcam (ab8245); 4Ebp1 total, Cell Signaling (9644); phospho-4Ebp1 (S65), Cell Signaling (9451); HIF1α, Cell Signaling (14179); VHL, Cell Signaling (68547), TFAM, Abcam (ab131607), and LC3B Cell Signaling (#2775)). After washes in TBS-Tween, the membranes were incubated with anti-mouse or anti-rabbit secondary antibodies (GE Healthcare, NA9310V and NA9340V) for 1 h at room temperature. Proteins were detected using Clarity Western ECL Substrate (Bio-Rad, 170-5061). Densitometric quantification of western blot bands was performed using the software Fiji normalized for the loading control.

**Oxygen consumption and extracellular acidification rates’ measurement**

Parental and resistant RKO cells were seeded in Seahorse XF96 culture dishes at a density of 1,000 cells per well and treatments were started 24 h after seeding. OCR and ECAR were measured simultaneously on a Seahorse XF96 analyzer (Agilent Technologies) in unbuffered DMEM containing glucose (10 mM), glutamine (2 mM), pyruvate (2 mM), and Heps (5 mM). After assessment of basal OCR and ECAR rates, sequential addition of oligomycin (oligo, 1 µM), carbonyl cyanide-p-(trifluoromethoxy)-phenylhydrazone (FCCP, 0.25 µM), rotenone/antimycin A (Rot, 1 µM/AA, 1 µM), and 2-deoxy-D-glucose (2DG, 50 mM) was performed. The optimal concentrations of these metabolic modulators were investigated in pre-experiments. Three independent experiments with at least six replicates were performed. After each experiment, OCR and ECAR values were normalized to corresponding cell numbers in each well using the CyQUANT assay (Thermo Fisher). Steady states of basal and maximal OCR or ECAR were calculated as the mean of three measurement cycles and were corrected for non-mitochondrial OCR (after Rot/AA addition) or non-glycolytic ECAR (after 2DG addition). Maximal OCR and ECAR corresponded to the steady states after injection of the ATP-synthese inhibitor oligomycin and uncoupler FCCP.

**Protein extraction, proteolytic digestion, and chemical labeling**

Cell pellets were suspended in 0.1% ProteaseMAX (Promega), 4 M urea (Sigma-Aldrich), 50 mM ammonium bicarbonate, and 10% acetonitrile (ACN). The samples were sonicated using Vibra-Cell probe (Sonics & Materials, Inc.) for 1 min, with pulse 2/2, at 20% amplitude, and sonicated in bath for 5 min, followed by vortexing and centrifugation for 5 min at 20,000 g. The supernatants were transferred to new tubes and the concentration was determined in a 1:10 dilution, in water. The protein yields were 500–1,300 µg.
Twenty-five micrograms (25 µg) of each sample was subjected to a tryptic digestion protocol including protein reduction in 6 mM dithiothreitol at 37°C for 60 min and alkylation in 22 mM iodoacetamide for 30 min at room temperature in the dark. Trypsin was added in an enzyme-to-protein ratio of 1:50 and digestion was carried out overnight at 37°C. Tryptic peptides were cleaned with C18 HyperSep Filter Plate, bed volume 40 µl (Thermo Scientific) and dried on a speedvac (miVac, Thermo Scientific). Six of TMT-10plex reagents (Thermo Scientific) in 100-µg aliquots were dissolved in 30-µl dry AcN, scrambled and mixed with the digested samples dissolved in 70 µl of triethylammonium bicarbonate (TEAB) (resulting final 30% AcN), followed by incubation at 22°C for 2 h at 550 rpm. The reaction mixture was then quenched with 12 µl of 5% hydroxyamine at 22°C for 15 min at 550 rpm. The labeled samples were pooled and dried on a speedvac (miVac, Thermo Scientific).

Liquid chromatography tandem mass spectrometry

Twenty micrograms of tandem mass tag (TMT)-labeled tryptic peptides was dissolved in 20 µl of 2% ACN/0.1% formic acid. Two µg samples were injected into a nano LC-1000 system online coupled to an Orbitrap Fusion mass spectrometer (Thermo Scientific, Bremen, Germany). The chromatographic separation of the peptides was achieved using a 50-cm long C18 EASY-spray column (Thermo Scientific), with the following gradient: 2–26% ACN in 110 min, 26–35% ACN in 10 min, 35–95% ACN in 5 min, and 95% ACN for 15 min at a flow rate of 300 nl/min. The MS acquisition method was comprised of one survey full scan ranging from m/z 375 to 1,500, acquired with a resolution of R = 120,000 (at m/z 200), followed by data-dependent higher-energy C-trap dissociation (HCD) fragmentations from maximum 15 most intense precursor ions with charge states 2+ and 7+. The tandem mass scans were acquired with a resolution of R = 60,000, targeting 5 × 10⁴ ions, setting isolation width to m/z 1.4, and normalized collision energy to 35%.

Proteomic data analysis

The raw data files were directly loaded in Proteome Discoverer v2.2 and searched against mouse or human SwissProt protein databases (42,793 and 21,008 entries, respectively) using the Mascot 2.5.1 search engine (Matrix Science Ltd.). Parameters were chosen as follows: up to two missed cleavage sites for trypsin, precursor mass tolerance 10 ppm, and 0.05 Da for the HCD fragment ions. Dynamic modifications of oxidation on methionine, deamidation of asparagine and glutamine, and acetylation of N-termini were set. For quantification, both unique and razor peptides were requested. The final quantitative data analysis was performed with an in-house developed R-studio script. Submitochondrial localization was based on the data extracted from (Vögtle et al., 2017). Human homologs were mapped with DIOPT v.8.0 (Hu et al., 2011) and filtered for proteins in human MitoCarta 2.0 (Calvo et al., 2016).

Measurement of intracellular IMT1 concentration

Parental and resistant RKO cells were seeded in triplicates in 12-well dishes at a density of 0.5 × 10⁶ cells per well in phenol-red free complete DMEM (Gibco 31053-028). Twenty-four hours after seeding, parental RKO cells were treated with either DMSO or 1 µM IMT1. IMT1-resistant cells were continuously grown in 1 µM IMT1. Samples were collected 0, 2, or 24 h after treatment, and the supernatant was transferred and snap-frozen. The cells were washed, acetoni trile (ACN) was added and incubated for 15 min at 4°C for cell extraction. The ACN extracts were transferred to a test tube and snap-frozen. Samples were analyzed by liquid chromatography–tandem mass spectrometry (LC–MS) using a Prominence UFLC system (Shimadzu) coupled to a Qtrap 5500 instrument (ABSciex). Prior to analysis, the samples were extracted with ACN containing internal standard, filtered, and diluted with water as necessary. The analytes were separated on a C18 column with an ACN and water mixture containing 0.1% formic acid as solvent using a gradient elution. Multiple reaction monitoring (MRM) transitions for each analyte were optimized automatically. Test article concentrations were calculated using a standard curve.

CRISPR-Cas9 5 screening

The human colon carcinoma cell line RKO (ATCC® CRL-2577™) was first made to stably express the Cas9 nuclease as described in (Schmierer et al., 2017). In brief, a construct coding for Cas9, blastidin resistance, and a single guide against hypoxanthine phosphoribosyltransferase 1 (HPRT1) was introduced with lentivirus transduction. This allows sequential selection with blastidin and 6-thioguanine, a nucleotide analog lethal in HPRT1− cells. Next, two replicates of approximately 150 M cells each were transduced with the genome-wide Brunello sgRNA library (Doench et al., 2016) at an MOI (multiplicity of infection) of 0.4 (> 600 cells/guide) in 2 µg/ml of polybrene. Transduced cells were selected with puromycin (1 µg/ml) from post-transduction days 2–7 and then allowed to grow for an additional 4 days without puromycin. Cells were subcultured when necessary, with cell number never dropping below 75 M. Cells were subcultured on post-transduction day 11, and on day 12 populations of 150 M cells were treated with either DMSO or 1 µM IMT1. After 10 days of treatment during which DMSO-treated cells were subcultured every 2–3 days and inhibitor-treated cells were subcultured once, cells were harvested, the DNA was isolated (Qiagen DNeasy Blood & Tissue kit), and guide sequences were amplified by PCR, as described in Schmierer et al. (2017). Pathway analysis performed using Reactome database (Jassal et al., 2019) on the top 50 significant enriched or depleted hits identified mTORC1 pathway as positive hit. Whereas, VHL gene was the most enriched and significant positive hit, whose loss rescued IMT1 toxicity.

Metabolite extraction for liquid chromatography mass spectrometry

RKO wild-type and IMT1-resistant cells were seeded into 6-well cell culture dishes (1 × 10⁶ cells per well). Twenty-four hours after seeding, the RKO cells were treated with either DMSO or 1 µM IMT1 for 96 h. Resistant RKO cells were kept in the continuous presence of 1 µM IMT1. Metabolites were extracted from parental and resistant RKO cells to determine basal differences in metabolite levels (0 h). After removal of the growth medium, the cells were washed twice with ammonium carbonate buffer (75 mM, pH 7.4) at 37°C. Metabolites were then extracted by two consecutive incubations with extraction buffer (40/40/20 (v/v/v) ACN/methanol/water, 10 ng/ml 13C10ATP, citric acid d4 (Sigma 710695, 485438), as well
as 2.5 mM uniformly $^{13}$C$_{15}$N-labeled amino acids (Cambridge Isotope Laboratories, MSK-A2-1.2)). The two extracts were pooled and centrifuged. The supernatants were transferred to new tubes and dried in a speed vac concentrator (Eppendorf). Samples were resuspended in 150 µl of liquid chromatography mass spectrometry (LC–MS)-grade H$_2$O (Thermo Fisher Scientific) of which, one aliquot (50 µl) was used to perform anion-exchange chromatography for the analysis of glycolysis, TCA, nucleotide and deoxy nucleotide metabolites. Another aliquot (50 µl) was used for the analysis of amine-containing metabolites. LC–MS analysis of amine-containing metabolites and anion-exchange chromatography mass spectrometry for the analysis of nucleotides, TCA cycle and glycolysis metabolites were performed, as previously described in Bonekamp et al. (2020). Each peak was normalized to the intensities of the appropriate internal standard that were spiked into the extraction buffer. Additionally, the peak intensities were normalized for the sample amount equivalent, hence the obtained protein concentration of each sample.

**Statistical analysis**

Data are expressed as mean values ± standard deviation (SD). Group mean values were analyzed using a two-tailed non-parametric Student's t-test, whereas multiple comparisons were performed with one-way ANOVA test. Comparisons were considered statistically significant for P values < 0.05 (*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001).

**Data availability**

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via Proteomics Identification Database (PRIDE) partner repository (Perez-Riverol et al., 2019) with the dataset identifier PXD026481 and will be available at the following link: https://www.ebi.ac.uk/pride/archive/projects/PXD026481

Expanded View for this article is available online.

**Acknowledgements**

This work was supported by the Swedish Research Council (2015-00438), Swedish Cancer Foundation, the Knut and Alice Wallenberg Foundation (KAW 2016-0050), European Research Council (ERC Advanced Grant 2016-74366), Novo Nordisk Foundation (NNF20OC063616), Diabetesfonden (DIA2020-516) and grants from the Swedish state under the agreement between the Swedish government and the county councils (SLL2018.0471). We thank Dr. Akos Vegvari from the Proteomics Biomedicum core facility, Karolinska Institutet for performing the mass spectrometry analyses and database search for protein identification and quantification. We are grateful to Florian Schober for his help with the proteomic data analyses. The CRISPR-Cas9 screen, next-generation sequencing and its analysis were carried out by Dr. Jenna Persson and Dr. Bernhard Schmierer at the High Throughput Genome Engineering Facility (HTGE). We acknowledge support from Science for Life Laboratory (SciLifeLab) and the National Genomics Infrastructure (NGI). Computations were performed on resources provided by SNIC (project SNIC 2017-7-265) to the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX). We thank Anke Unger from the Lead Discovery Center GmbH for the measurement of intracellular and extracellular IMT concentrations. The synopsis image and the scheme in Fig 1 were created with www. BioRender.com.

**Author contributions**

MM and N-GL conceived the project, designed the experiments, and wrote the manuscript. MM performed the majority of the experiments. RF, AF, NAB, and OL performed experiments and analyzed the data generated. PG performed the metabolomics analyses. N-GL supervised the project. All authors gave input on the manuscript.

**Conflict of interest**

The IMT compound intellectual property is published as WO 2019/057821 and has been licensed by the Max Planck Society and the Lead Discovery Center GmbH. NGL is a scientific founder and holds stock in Pretzel Therapeutics, Inc.

**References**

Anderson S, Bankier AT, Barrell BG, de Bruijn MHL, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F et al (1981) Sequence and organization of the human mitochondrial genome. Nature 290: 457 – 465

Bibb MJ, Van Etten RA, Wright CT, Walberg MW, Clayton DA (1981) Sequence and gene organization of mouse mitochondrial DNA. Cell 26: 167 – 180

Bonekamp NA, Jiang M, Motori E, Villegas RG, Koolmeister C, Atanassov I, Mesaros A, Park CB, Larsson N-G (2021) High levels of TFAM repress mammalian mitochondrial DNA transcription in vivo. Life Sci Alliance 4: e20210134

Bonekamp NA, Peter B, Hillen HS, Felser A, Bergbrede T, Choidas A, Horn M, Unger A, Di Lucrezia R, Atanassov I et al (2020) Small-molecule inhibitors of human mitochondrial DNA transcription. Nature 588: 712 – 716

Boukalova S, Stursa J, Werner L, Ezrova Z, Cerny J, Bezawork-Geleta A, Pecinova A, Dong L, Drahota Z, Neuzil J (2016) Mitochondrial targeting of metformin enhances its activity against pancreatic cancer. Mol Cancer Ther 15: 2875 – 2886

Calvo SE, Clauser KR, Mootha VK (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res 44: D1251 – D1257

Chinnery PF (2015) Mitochondrial disease in adults: what’s old and what’s new? EMBO Mol Med 7: 1503 – 1512

Chomyn A (1996) In vivo labeling and analysis of human mitochondrial translation products. Methods Enzymol 264: 197 – 211

Choo AV, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon S-O, Cantley LC, Blenis J (2010) Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38: 487 – 499

Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R et al (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34: 184 – 191

Ferrari M, Jain IH, Goldberger O, Rezogoli E, Thoenen R, Cheng K-H, Sosnovik DE, Scherrer-Crosbie M, Mootha VK, Zapol WM (2017) Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. Proc Natl Acad Sci USA 114: E4241 – E4250

Filograna R, Koolmeister C, Upadhyay M, Pajak A, Clemente P, Wibom R, Simard ML, Wredenberg A, Freyer C, Stewart JB et al (2019) Modulation of mtDNA copy number ameliorates the pathological consequences of a heteroplasmic mtDNA mutation in the mouse. Sci Adv 5: eaav9824

Filograna R, Mennuni M, Alsina D, Larsson N-G (2021) Mitochondrial DNA copy number in human disease: the more the better? FEBS Lett 595: 976 – 1002
Fumanoleta C, La Monica S, Alfieri RR, Borra E, Guidotti GG (2005) Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 12: 1344 – 1357
Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, Clements MO, Bourbouilla D, Pedley RB, Moncada S et al (2007) Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 104: 6223 – 6228
Gammage PA, Frezza C (2019) Mitochondrial DNA: the overlooked oncogene? BMC Biol 17: 53
Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, Gopal RK, Calvo SE, Shih AR, Chaves FL, McGuone D, Mick E, Pierce KA, Li Y, Jain IH, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger Heitman J, Movva NR, Hall MN (ª)
Mara Mennuni et al
Guenzler-Pukall V, Neff TB, Wang Q, Arend MP, Flippin LA, Melekhov A (2019) An integrative approach to ortholog prediction for disease-focused knowledgebase. EMBO reports
Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Jia X, Gu Z, Chen W, Jiao J
Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A et al (2014) Ongoing and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife 3: e02935
Kaelin Jr WG (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865 – 873
Katigbak A, Cencic R, Robert F, Sénécha P, Scuccpo C, Pelletier J (2016) A CRISPR/Cas9 functional screen identifies rare tumor suppressors. Sci Rep 6: 38968
Kauppila J, Baines H, Bratic A, Simard M-L, Freyer C, Mourier A, Stamp C, Filogrina R, Larsson N-G, Creaves L et al (2016) A phenotype-driven approach to generate mouse models with pathogenic mtDNA mutations causing mitochondrial disease. Cell Rep 16: 2980 – 2990
Kauppila TES, Kauppila JHK, Larsson N-G (2017) Mammalian mitochondria and aging: an update. Cell Met 25: 57 – 71
Khan NA, Nikkanen J, Yatsuga S, Jackson C, Wang L, Pradhan S, Kivelä R, Pessia A, Velagapudi V, Suomalainen A (2003) Stabilization of Hypoxia-Inducible Factor (HIF) alpha. WO2003049686A2, Caplus AN 2003:473343
Gustafsson CM, Falkenberg M, Larsson NG (2016) Maintenance and expression of mammalian mitochondrial DNA. Annu Rev Biochem 85: 133 – 160
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646 – 674
Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905 – 909
Hensley C, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L et al (2016) Metabolic heterogeneity in human lung tumors. Cell 164: 681 – 694
Hillen HS, Temiaiov D, Cramer R (2018) Structural basis of mitochondrial transcription. Nat Struct Mol Biol 25: 754 – 765
Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, Mohr SE (2011) An integrative approach to ortholog prediction for disease-focused and other functional studies. BMC Bioinformatics 12: 357
Hung C-M, Garcia-Haro L, Sparks CA, Guertin DA (2012) mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 4: a003871
Jain IH, Zazzeron L, Gori R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberg O, Peng J, Shalem O, Sanjana NE et al (2016) Hypoxia as a therapy for mitochondrial disease- supplementary. Science 352: 54 – 61
Jain IH, Zazzeron L, Goldberg O, Marutani E, Wojtkiewicz GR, Ast T, Wang H, Schleifer G, Stepanova A, Brepoels K et al (2019) Leigh syndrome mouse model can be rescued by interventions that normalize brain hyperoxia, but not HIF activation.
Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR (2018) Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases. J Med Chem 61: 6964 – 6982
Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A et al (2014) Ongoing and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife 3: e02935
Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC
Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2016) Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet 29: 151 – 178
Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P et al (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature 568: 254 – 258
Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271 – 275
McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O’Donovan N, Stordal B (2014) In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol 4: 40
McKee EE, Ferguson M, Bentley AT, Marks TA (2001) An inhibitor of mTOR reduces neoplasia targeted therapy-resistant chronic myeloid leukemia stem cells. Nat Med 23: 1234 – 1240
Larsson N-G, Clayton DA (1995) Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet 29: 151 – 178
Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P et al (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature 568: 254 – 258
Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271 – 275
McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O’Donovan N, Stordal B (2014) In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol 4: 40
McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50: 2042 – 2049
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583 – 592
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfOso T, Morlacchi P, Ackroyd J, Agip NA et al (2018) An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 24: 1036 – 1046
Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187 – 197
Perez-Riverol Y, Czordas A, Bai J, Bernal-Linares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J, Mayer G, Eisenacher M et al (2019) The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47: D442
Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Nesbat M, Wang H, Yang L, Gibbons J et al (2001) An inhibitor of mTOR reduces neoplasia
and normalizes p70S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci USA 98: 10320 – 10325
Rabinowitz MH (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem 56: 9369 – 9402
Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y et al (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5: 3031 – 3040
Reznik ED, Miller ML, Şenbabaoğlu Y, Riaz N, Sarungbam J, Al-Ahmadi HA, Lee W, Seshan VE, Hakimi AA et al (2016) Mitochondrial DNA copy number variation across human cancers. Elife 5: 1 – 20
Rini BI (2008) Temsiroliimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14: 1286 – 1290
Sayed S, Paszkowski-Rogacz M, Schmitt LT, Buchholz F (2019) CRISPR/Cas9 as a tool to dissect cancer mutations. Methods 165: 36 – 48
Schmierer B, Botla SK, Zhang J, Turunen M, Kvioja T, Taipale J (2017) CRISPR/Cas9 screening using unique molecular identifiers. Mol Syst Biol 13: 945
Shegal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,898), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28: 727 – 732
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Shi Y, Lim SK, Liang Q, Iyer SV, Wang H-Y, Wang Z, Xie X, Sun D, Chen Y-J (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84 – 87
Sharma S, Petsalaki E (2018) Application of CRISPR/Cas9 based genome-wide screening approaches to study cellular signalling mechanisms. Int J Mol Sci 19: 933
Shi Y, Lim SK, Liang Q, Iyer SV, Wang H-Y, Wang Z, Xie X, Sun D, Chen Y-J, Tabar V et al (2019) Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma HHS public access. Nature 567: 341 – 346
Škrščić M, Srisukhthavean S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N et al (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20: 674 – 688
Sterky FH, Hoffman AF, Milenkovic D, Bao B, Paganelli A, Edgar D, Wisbon R, Lupica CR, Olson L, Larsson N-G (2012) Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum Mol Genet 21: 1078 – 1089
Stewart JB, Alaei-Mahabadi B, Sabarinathan R, Samuelsson T, Gorodkin J, Gustafsson CM, Larsson E (2015) Simultaneous DNA and RNA mapping of somatic mitochondrial mutations across diverse human cancers. PLoS Genet 11: 1 – 15
Stewart JB, Chinnery PF (2015) The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet 16: 530 – 542
Sun S-Y (2013) mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 340: 1 – 8
Swanton C (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res 72: 4875 – 4882
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottisman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219 – 234
Thimmiaiah KN, Easton JB, Houghton PJ (2010) Protection from rapamycin-induced apoptosis by insulin-like growth factor-1 is partially dependent on protein kinase C signaling. Cancer Res 70: 2000 – 2009
Valle S, Martin-Hijano L, Alcalá S, Alonso-Nocelo M, Sainz Jr B (2018) The ever-evolving concept of the cancer stem cell in pancreatic cancer. Cancers 10: 33
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029 – 1033
Vasan K, Werner M, Chandel NS (2020) Mitochondrial metabolism as a target for cancer therapy. Cell Metab 32: 341 – 352
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V et al (2014) Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514: 628 – 632
Villar VH, Nguyen TL, Delcroix V, Terés S, Boucheclarelh M, Salin B, Bodineau C, Vacher P, Priault M, Soubyran P et al (2017) mTORc1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nat Commun 8: 14124
Vogtле F-N, Burkhart JM, Gonzarovskaja-Jorge H, Küçükçüko ğ C, Taskin AA, Kopczynski D, Ahrends R, Mrossmann D, Sickmann A, Zahedi RP et al (2017) Landscape of submitochondrial protein distribution. Nat Commun 8: 290
Wang GL, Semenza GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304 – 4308
Woodward GE, Hudson MT (1954) The effect of 2-desoxy-d-glucose on glycolysis and respiration of tumor and normal tissues. Cancer Res 14: 599 – 605
Yang J, Zhou R, Ma Z (2019) Autophagy and energy metabolism. Adv Exp Med Biol 1206: 329 – 357
Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincocena I, Creighton CJ, Weinstein JN et al (2020) Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet 52: 342 – 352
Zhang H, Gao P, Fukuda R, Kumar G, Krishnamacharya B, Zeller KL, Dang CV, Semenza GL (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407 – 420
Zheng X, Boyer L, Jin M, Kim Y, Fan W, Bardy C, Berggren T, Evans RM, Gage FH, Hunter T (2016) Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. Elife 5: e13378
Zhao T, Sang Y-H, Cai S, Xu C, Shi M (2021) The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth. Cell Death Dis 12: 1 – 12

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.